Every Form 4 that Rallybio Corporation (RLYB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RLYB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLYB filings page.
Rallybio Corp (RLYB) director Wendy Chung exercised stock options into common shares. On September 16, 2026, she exercised options for 3,562 shares of common stock at an exercise price of $2.38 per share, converting an option position into directly held stock.
The exercised option for 3,562 underlying shares now shows 0 options remaining from that grant, while her direct ownership in Rallybio common stock is reported as 3,562 shares following the transaction. No Rule 10b5-1 trading plan is reported for this activity.
Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026 at an exercise price of $2.38 per share. Following the transaction, she directly holds 6,542 shares of Common Stock. The options exercised were originally rights to buy Rallybio common stock.
Rallybio Corp disclosed that private investment funds and separately managed accounts managed by ADAR1 Capital Management, LLC made open-market purchases of Rallybio common stock. Across May 18–19, 2026, these ADAR1-managed vehicles bought a total of 16,209 shares at weighted average prices near $14 per share.
Following these transactions, the ADAR1-managed funds and accounts indirectly held 926,352 Rallybio shares. ADAR1 Capital Management and Daniel Schneeberger, each a 10% owner, may be deemed indirect beneficial owners but expressly disclaim beneficial ownership beyond any pecuniary interest.
Rallybio Corp reported insider-related buying activity by entities associated with ADAR1 Capital Management, LLC and Daniel Schneeberger. Private funds and separately managed accounts managed by ADAR1 purchased a total of 79,559 shares of Rallybio common stock in open-market transactions on May 13, 2026 and May 15, 2026.
Reported purchase prices ranged from $13.7700 to $14.0000 per share, with some trades disclosed on a weighted-average basis. The filing states these securities are owned directly by ADAR1-managed investment vehicles and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest.
Rallybio Corp reported that private investment funds and separately managed accounts managed by ADAR1 Capital Management, LLC, which may be deemed to be indirectly beneficially owned by ADAR1 and Daniel Schneeberger, completed a series of open-market purchases of common stock. On May 11–12, 2026, these accounts bought a total of 50,800 shares of Rallybio common stock in four transactions at weighted average prices around $13.83–$14.00 per share, within disclosed trading ranges from $13.75 to $14.00. Following the most recent transaction, the filing reports 830,584 shares indirectly owned. The reporting persons disclaim beneficial ownership of the securities beyond any pecuniary interest.
Rallybio Corp reported that private investment funds and separately managed accounts overseen by ADAR1 Capital Management, LLC made open‑market purchases of its common stock. Across three transactions on May 4–5, 2026, these accounts bought 155,905 shares at per‑share prices around $13.9–$14.0, increasing their indirect position to 779,784 shares. The securities may be deemed indirectly beneficially owned by ADAR1 and by Daniel Schneeberger, though each reporting person disclaims beneficial ownership beyond any pecuniary interest.
Rallybio Corp Chief Financial Officer Jonathan I. Lieber reported mixed stock transactions. On February 18, 2026, he acquired 2,500 shares of Rallybio common stock as a grant or award at $0.00 per share. On February 23, 2026, he sold 789 shares of common stock at an average price of $5.06 per share, and a footnote explains this sale was made solely to cover tax withholding obligations from the vesting of a performance stock award. Following these transactions, he directly holds 4,115 shares of Rallybio common stock.
Rallybio Corp director Martin Mackay received a stock option grant tied to his board compensation. The Form 4 shows an award of options to purchase 18,055 shares of common stock at an exercise price of $3.60 per share.
The option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $65,000 in retainer fees. It vests in 11 equal installments, each on the last day of the remaining months of calendar year 2026, meaning the award becomes exercisable gradually over that period rather than all at once.
Rallybio Corp director Ronald Hunt received an option grant to acquire 14,305 shares of common stock at $3.60 per share. The option was issued under the 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees and vests in 11 equal monthly installments over the remaining months of 2026.